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Abstract 
Background: Cases of ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) gram-negative bacilli 
(GNB) mainly Acinetobacter baumannii, Pseudomonas aeruginosa and enterobacteria are common in hospitalised 
patients of Tunisian intensive care units (ICUs). Parenteral colistin has been used for the therapy of VAP caused by MDR 
GNB at Tunisian hospitals over the past few years with a favourable clinical response. However, its use fell out of favour 
because of the reported drug-related nephrotoxicity and neurotoxicity.
Objectives: To determine whether aerosolised (AS) colistin was beneficial and safe in therapy of gram-negative VAP.
Methods: This was a randomised, single-blind study, in 149 critically ill adults who developed gram-negative VAP. 
Included patients were divided into two groups whether they received AS colistin (intervention group; n = 73) or intra-
venous (IV) colistin (control group; n = 76). AS colistin was given as 4 million units (MU) by nebulisation three times per 
24 h. IV colistin was given as a loading dose of 9 MU followed by 4.5 MU two times per 24 h. Patients were followed dur-
ing 28 days. Primary outcome was cure of VAP assessed at day 14 of therapy and defined as resolution of clinical signs 
of VAP and bacteriological eradication. Secondary outcomes were incidence of acute renal failure (ARF), mechanical 
ventilation length, ICU length of stay and 28-day mortality. Results were analysed based on intention-to-treat concept.
Results: The patient’s baseline characteristics and distribution of pathogens VAP in both groups were similar. The clini-
cal cure rate was 67.1 % in AS group and 72 % in IV group (p = 0.59). When administered in monotherapy or in com-
bination, the AS regimen was as effective as IV regimen. Patients in AS group had significantly lower incidence of ARF 
(17.8 vs 39.4 %, p = 0.004), more favourable improvement of P/F ratio (349 vs 316 at day 14, p = 0.012), shortened time 
to bacterial eradication (TBE) (9.89 vs 11.26 days, p = 0.023) and earlier weaning from ventilator in ICU survivors with a 
mean gain in ventilator-free days of 5 days. No difference was shown in the length of stay and the 28-day mortality.
Conclusion: Aerosolised colistin seems to be beneficial. It provided a therapeutic effectiveness non-inferior to paren-
teral colistin in therapy of MDR bacilli VAP with a lower nephrotoxicity, a better improvement of P/F ratio, a shortened 
bacterial eradication time and earlier weaning from ventilator in ICU survivors.
Trial registration ClinicalTrials.gov Identifier: NCT02683603
Keywords: Colistin, Aerosol, Ventilator-associated pneumonia, Nephrotoxicity, Intravenous
© 2016 Abdellatif et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Ventilator-associated pneumonia (VAP) is the most 
common healthcare-associated infection causing mor-
bidity and mortality [1]. Overall attributable mortality 
rates were between 5.8 and 27 % [1, 2]. In the past dec-
ade, multidrug-resistant (MDR) gram-negative bacteria 
(GNB) have become the focus of increased attention. 
Worldwide, as in Tunisia, there are growing threats to 
modern medicine from the emergence of MDR bacte-
ria causing nosocomial infection. In Tunisian ICU, the 
most cases of VAP in patients are caused by GNB, pre-
dominantly Acinetobacter baumannii, Pseudomonas 
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aeruginosa and Klebsiella pneumonia [3, 4]. Resistance 
of these MDR pathogens to β-lactams, including car-
bapenems, aminoglycosides and fluoroquinolones, was 
increasingly observed from patients with VAP [3, 4]. The 
virulence of such pathogens severely restricts viable ther-
apeutic options. MDR A. baumannii, P. aeruginosa and 
K. pneumonia in Tunisian ICU are almost always sus-
ceptible to colistin, and parenteral colistin has been used 
in more than 90  % of nosocomial infections [5]. At our 
institution, over the past few years, the use of intravenous 
colistin was often associated with occurrence of side 
effects, mainly nephrotoxicity and neurotoxicity. Sev-
eral studies on the therapy of MDR bacteria pneumonia 
with nebulised colistin revealed a trend of favourable use. 
Thus, the inhaled route may offer the benefit of an effec-
tive alveolar penetration with a low systemic diffusion 
[6]. Some reports with other antibiotics had approved 
the interest of such modality. Aerosolised aztreonam was 
recommended in cystic fibrosis since 2010 [7]. Tobramy-
cin, aztreonam and colistin were assessed as adjunctive 
therapy with successful results [8–10].
The objective of the study was to determine whether 
aerosolised colistin was effective and safe in therapy of 
MDR bacilli VAP in comparison with intravenous colistin 
in a prospective randomised trial fashion.
Methods
Study design
This study was designed as a single-centre, prospec-
tive, randomised single-blind trial. It was conducted in a 
medical ICU of a tertiary care university teaching hospi-
tal during 25 months, from April 2013 to April 2015. The 
study protocol was approved by the ethics committee of 
the institutional review board of La Rabta Hospital.
Patients and randomisation
All critically ill patients older than 18 years, with mechani-
cal ventilation during more than 48 h, and who have pre-
sented a VAP, were eligible for study entry. Age <18 years, 
pregnancy and septic shock were considered as exclusion 
criteria. Patients who did not meet any exclusion crite-
ria were randomly assigned into an intervention group 
and a control group (AS vs IV). Block randomisation was 
conducted by a random selection of computer-generated 
algorithm, the allocation sequence was followed by an inde-
pendent statistician, and communicated to the investigator.
In the following cases: suspension of colistin (multisen-
sitive strain imposing de-escalation, or a colistin-resistant 
strain), occurrence of a major side effect of inhaled route 
(severe bronchospasm or alveolar haemorrhage), decline 
in creatinine clearance below 10 ml/min in 48 h, occur-
rence of bacteraemia and/or septic shock, the patient 
should leave the trial protocol.
Study intervention
Colistin used was colimycine® powder (Sanofi Win-
throp Industrie), i.e. colistimethate sodium—CMS. A fla-
con of 1 million units (MU) of colimycine® = 80 mg of 
CMS = 33.3 mg of colistin base activity.
Included randomised patients were treated with an 
empirical anti-infective therapy combining imipenem 
and colistin, depending on our local bacterial ecology. 
According to the randomisation, patients were divided 
into two groups: intervention and control groups. The 
intervention group (AS group) received 4 million units 
(MU) of AS colistin by nebulisation for 30  min three 
times per day in addition to IV imipenem 1  g three 
times per day. Nebulisation was made via an ultrasonic 
vibrating plate nebuliser (Aeroneb Pro® Aerogen Nektar 
Corporation, Galway, Ireland). This technique required 
specific settings in order to limit turbulence inspiratory 
flow. The specific settings were: a volume controlled 
mode with a tidal volume <8 ml/kg, respiratory rate at 12 
cycles/min, I/E: 1/1 and an end inspiratory break >20 %.
The control group (IV group) received IV colistin as a 
loading dose of 9 MU during 60 min followed by 4.5 MU 
two times per day combined to IV impenem 1  g three 
times per day.
 According to anti-infective susceptibility results, a tar-
geted therapy was started. If the strain was sensitive to 
other anti-infective drugs, colistin was combined with 
β-lactam or aminoglycoside or tygecyclin. If the isolated 
pathogen was a colistin-only susceptible, colistin was 
administered in monotherapy.
The treatment duration was maintained at least 14 days. 
After extubation, AS colistin dose was calculated accord-
ing to a 40  % extra pulmonary deposition, as shown in 
experimental studies [11]. Thus, the prescribed dose was 
modified to 7 MU in the nebuliser chamber, equivalent to 
a delivered dose of 4.2 MU in the respiratory tract.
In case of renal insufficiency, the relay doses of IV colis-
tin were modified according to the creatinine clearance as 
follows: 4.5 MU per day if 10 ml/min < clearance < 30 ml/
min, and 4.5 MU per 48 h if clearance is less than 10 ml/
min. The loading dose of 9 MU was maintained.
Definitions and data collection
At study entry, demographic data, co-morbidities and the 
admission diagnosis were collected.
An episode of VAP was defined as a Clinical Pulmo-
nary Infection Score (CPIS) of more than six [12, 13]. 
The investigators calculated the CPIS when the patient 
presented features suggesting a VAP such as fever, leu-
kocytosis, purulent secretions, hypoxemia or radiological 
infiltrate. In case of the CPIS was higher than 6 points, 
the diagnosis of VAP was suspected and a tracheal aspi-
rate was performed before colistin administration.
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Bacteriological samples were performed on tracheal aspi-
rate. A positive tracheal sample was defined as more than 
or equal to 106 colony-forming units (CFU)/ml. Sensitivity 
to colistin was determined by the E test, and the isolated 
strain was considered sensitive when the minimum inhibi-
tory concentration (MIC) was less than 2 mg/l. Microbio-
logical eradication was defined as a negative culture, i.e. no 
pathogen isolated in tracheal aspiration. The oxygenation 
was assessed by the PaO2/FiO2 ratio, and its improvement 
was considered when the ratio exceeded 300.
The acute renal failure (ARF) was defined as an increase 
of plasma creatinine more than 1.5 times its base value.
Outcome assessment
Patients were followed during 28 days. A physical exami-
nation (including temperature measurement and exami-
nation of tracheal secretions aspect) and a biological 
exploration including blood cells count, arterial blood 
gas and renal function were conducted every day. Chest 
X-ray and tracheal aspirate culture were performed every 
3 days.
Therapeutic efficacy was assessed by the cure of VAP at 
the end of colistin therapy (day 14). The cure of VAP was 
defined as the resolution of clinical and biological signs 
of infection, i.e. a CPIS less than 6 and bacteriological 
eradication. Secondary outcomes were incidence of ARF, 
mechanical ventilation length, ICU length of stay and 
28-day mortality.
Post‑therapy assessment
A clinical, biological and bacterial re-assessment was 
performed at day 7 of the anti-infective cure, by the CPIS 
calculation and renal function analysis. The tracheal aspi-
rate was replaced by cyto-bacteriological sputum in case 
of ventilator weaning.
Statistical analysis
We estimated that a sample size of 149 patients (AS, 
n = 73 and IV, n = 76) would provide a power of 80 % to 
demonstrate the non-inferiority of AS regimen compared 
with parenteral colistin with a lower toxicity in the inter-
vention arm at a two-sided alpha error of 5 %. All statis-
tical analyses were based on intention-to-treat principle.
Quantitative data were reported as mean  ±  SD and 
compared by the Student’s t test or the Mann–Whitney 
U test, as appropriate. Qualitative data were expressed as 
percentages and compared by the Chi-square or Fisher’s 
exact tests, as appropriate. The risk association meas-
urement was expressed as odds ratio and performed by 
stratified analysis. Survival analysis was processed by the 
Kaplan–Meier survival curves and compared by the log-
rank test. All tests were two-sided, and a p value <0.05 
was considered to indicate statistical significance. The 




One hundred and forty-nine patients have met our eligi-
bility criteria. There were 73 evaluable patients in the AS 
group and 76 evaluable patients in the IV group. One hun-
dred and thirty-three patients received allocated interven-
tion and followed during the study period in accordance 
with the trial rules, while 16 patients did not receive allo-
cated intervention. The two study groups were divided 
into two subgroups whether they received colistin alone or 
combined. The study flow diagram is shown in Fig. 1.
The demographic data, co-morbidities, admission 
diagnoses, the ICU stay before inclusion, pre-exposure 
to previous antibiotics and systemic antibiotics of the 
patients in both groups were not significantly different. 
When anti-biogram was available, in a median time of 
3.6 days (the same period of empirical anti-infective ther-
apy), colistin was continued either in combination (AS 
group; n = 60 and IV group; n = 64) or as monotherapy 
(AS group; n = 13 and IV group; n = 12). Carbapenems, 
β-lactam/β-lactamase inhibitors were the common anti-
biotics given in combination with colistin (Table 1).
In 123 (82.5 %) of the studied samples [AS group, n = 59 
(81 %), and IV group, n = 64 (84.2 %)], a causing pathogen 
of VAP was isolated. The common causative bacteria iso-
lates were A. baumannii, P. aeruginosa and K. pneumonia. 
There was no significant difference in microorganism’s dis-
tribution between the study groups: p = 0.65 (Fig. 2).
In case of VAP without isolated pathogen, the empiri-
cal therapy by imipenem/colistin according to randomi-
sation was maintained.
Therapeutic efficacy assessment
Forty-nine patients of the AS group (67.1 %) had a favour-
able clinical outcome of VAP versus 72.3 % in IV group (p 
value = 0.59). Thus, efficacy of AS colistin in treatment of 
VAP was not inferior to IV colistin. Likewise, AS colistin 
was as effective as IV colistin; regardless it was admin-
istered as monotherapy or in combination. Rather, the 
observed cure rate with a monotherapy administration 
was greater than AS route but without statistical signifi-
cance (Fig. 3).
Assessment of efficacy items
All patients at inclusion have a radiological infiltrate 
among which the localised topography was more com-
mon than diffuse infiltration (64 % in AS arm and 68 % IV 
arm). Radiographic progression was observed 3 days later 
in 18 patients among AS group and 13 patients among 
IV group without significant difference (p  =  0.41). The 
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radiological clean-up was obtained in all patients with a 
favourable outcome.
In cured patients, the mean P/F ratio was significantly 
improved with AS colistin group at day 14 of colistin therapy. 
Microbiological outcomes did not differ in the negativity of 
samples, while, regarding the time to bacterial eradication 
(TBE), it was shortened by an average of 2 days in AS group 
(9.89 ± 2.7 vs 11.26 ± 3 days, p = 0.023) (Fig. 4).
Randomizaon by block of 4 paents sequenally *    
     Targeted therapy                          Targeted therapy 
Excluded  (n = 7): 
Sensive strain (n=4)
Sepc shock (n = 2) 
Bacteraemia (n = 1)
Received allocated intervenon 
according to the trial rules (n=66)  
Excluded (n = 9): 
Sensive strain (n=5) 
Sepc shock (n = 4)
Received allocated intervenon 
according to the trial rules (n=67) 
AS Colisn in 
monotherapy: 
COS strain (n=13) 
AS Colisn in 
combinaon* 
 (n=42) 
IV Colisn in 
monotherapy: 
COS strain (n=12) 









IV colisn + 
Imipenem (n=76) 













Eligible parcipants who 
From April 2013 to 2015 
presented a VAP:  CPIS>6           
(n=149) 
Decision of Empirical therapy (IV imipenem 
1 g x3/ day+ colisn according to 
randomizaon) has been taken  
Fig. 1 Patients’ flowchart. VAP ventilator-acquired pneumonia, CPIS Clinical Pulmonary Infection Score, AS aerosolised, IV intravenous, COS colistin-
only susceptible. *The order of randomization was as follows: Block 1: AS, AS, IV, IV; Block 2: AS, IV, AS, IV; Block 3: IV, IV, AS, AS; Block 4: IV, AS, IV, AS. 
Details of combination are displayed in Table 1
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Systemic toxicity assessment
The incidence of acute renal failure (ARF) was sig-
nificantly lower with AS administration. It occurred in 
17.8 % of patients in the AS group compared with 39.4 % 
of patients in the IV group. Also, the replacement renal 
therapy (RRT) was less required with AS group (30.7 vs 
40  %, p =  0.032). In the same way, the ARF onset was 
later in AS arm (8.69 v 5.07  days, p  <  10−3) (Fig.  5). A 
stratified analysis on nephrotoxic agents (aminogly-
cosides, glycopeptides and iodinated contrast agents) 
showed a significant association between renal impair-
ment and IV colistin (OR 2.79, 95  % CI [1.23; 6.32], 
p = 0.01).
A probable colistin-induced neurotoxicity occurred in 
9 (12 %) and 7 (9.2 %) among AS and IV groups, respec-
tively, without difference (p = 0.66). But, the causal rela-
tionship to colistin was difficult to establish because of 
other medications that could interfere (corticosteroids 
and neuromuscular blocking agents).
Table 1 Baseline demographic and patients’ clinical characteristics
AS aerosolised, IV intravenous, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, SD standard deviation
AS colistin group (n = 73) IV colistin group (n = 76) p value
Age: age (mean + SD) 50 ± 16 53 ± 17 0.28
Sex ratio 2.31 1.81 0.49
SAPS II at inclusion 39 + 13 40 + 14 0.65
SOFA at inclusion 7.03 + 3.8 6.5 + 4.1 0.43
Reasons for admission [n (%)]
 Respiratory distress 32 (44 %) 29 (38 %)
 Neurological causes 23 (31.5 %) 26 (34 %)
 Metabolic disorders 11 (15 %) 15 (20 %)
 Intoxications 5 (7 %) 3 (4 %)
 Others 2 (2.5 %) 3 (4 %) 0.92
Length of stay before inclusion: days [mean + SD (median)] 11.28 ± 9 (9) 11.14 ± 8.8 (9) 0.49
Previous antibiotic use [n (%)] 49 (67 %) 46 (60 %) 1
Colistin in monotherapy [n (%)] 13 (17.8 %) 12 (15.7 %) 1
Co-administered antibiotics [n (%)] 60 (80.3 %) 64 (82 %) 0.62
 β-lactams 32 37 1
 Aminoglycosides 11 12 1
 Quinolones or macrolides 5 6 0.79
 Tygecyclin 8 8 0.58
 Glycopeptides 8 6













IV colisn group  (64 documented VAP/76)
AS colisn group (59 documented VAP/73)


























Fig. 3 Cure rates between the study groups. The cure rates were 
shown when colistin was prescribed in monotherapy, in combination 
or both
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Local toxicity assessment
Most of the patients tolerated nebulised colistin therapy 
well. A moderate bronchospasm was observed in 2.7 % of 
patients in the AS group. It was managed by bronchodila-
tors without recurrence.
No difference was observed in other secondary out-
comes: mechanical ventilation length (13.8  ±  7 vs 
16.5 ± 10, p = 0.083), ICU length of stay (25.9 ± 17 vs 
26.07 ± 17, p = 0.9) and the all-cause mortality at 28 days 
(27.4 vs 23.7 %, p = 0.7) between AS and IV arms, respec-
tively. Similarly, survival analysis did not differ (Fig. 6).
Nevertheless, the results change with the ventilator 
days when only ICU survivors were included in the analy-
sis (Fig. 7). Indeed, the weaning from ventilator was sig-
nificantly earlier with AS group (13 vs 18 days; p = 0.012) 
with a mean gain in ventilator-free days of 5 days.
Post‑therapy assessment
Ninety patients were re-assessed at 7  days after colis-
tin therapy (AS group; n  =  46 and IV group; n  =  44). 
Thirty-one patients died before this time, and 12 patients 
lost to follow-up.
No difference in CPIS was shown in both groups (3.8 
vs 4.5, p =  0.12). In cured patients, the CPIS was more 
enhanced with AS group (3.02 vs 3.68, p = 0.027) (Fig. 8). 
In case of clinical failure, the antibiotic therapy was pro-
longed or modified.
Respiratory samples were positive in 13 cases. We diag-
nosed a persistent VAP in four cases and colonisation in 
nine cases. Identified pathogens were: Pseudomonas spp. 
and Acinetobacter baumannii that maintained suscepti-
bility to colistin. Others were Serratia, Providencia and 
Proteus.
The renal impairment was reversible in 78  % of AS 
group and 54 % of IV group (p = 0.38).
Discussion
To the best of our knowledge, the present study is among 
the few randomised trials if not the only to date that 
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Fig. 4 a Evolution of P/F ratio in both groups. b Evolution of positivity rate of bacteriological samples in both groups. c Time to bacterial eradication 
(TBE) between groups
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compared with parenteral colistin and not as adjunctive 
therapy to intravenous colistin in patients with gram-
negative VAP. We demonstrate that nebulised colistin 
was as effective as IV colistin in therapy of VAP caused by 
MDR bacteria regardless of its prescription in combina-
tion or monotherapy (67.1 vs 72 %, p = 0.59). The benefit 
of such modality was shown at several points: a signifi-
cant lower incidence of nephrotoxicity (17.8 vs 39.4  %, 
p =  0.004), a greater improvement of P/F ratio, a faster 
time to pathogen eradication and an earlier weaning 
from ventilator in ICU survivors.
Rationale for using aerosolised antibiotics
The rationale for inhaling antibiotics is to maximise drug 
delivery to the target site of infection (i.e. the airways) 
and limit the potential for systemic side effects [14]. A 
major therapeutic advance of such modality took place in 
patients with cystic fibrosis chronically colonised with P. 
aeruginosa [7, 8, 15, 16]. Inhaled antibiotics were evalu-
ated also in non-cystic fibrosis bronchiectasis with clini-
cal benefits [17, 18]. In the experimental study of Lu et al. 
[11], colistin was found undetected in the lung tissue 
after intravenous infusion, while after nebulisation, peak 
lung tissue concentrations were significantly higher in the 
lung segments. The enhancement of the local bactericidal 
activity and the low systemic toxicity were also reported 
in a several experimental studies [6, 11, 19].
Clinical benefits of aerosolised colistin in MDR bacteria VAP
 The majority of studies focused on inhaled colistin 
evaluated the efficacy and safety of nebulised colistin as 
adjunctive therapy to intravenous colistin compared with 
IV colistin [20–24] or compared with other antibiotics 
such as β-lactams [9], doxycycline [25] or tygecyclin [26]. 
The key results of these studies, separately or included in 
meta-analysis, were concordant in the beneficial effect 
of inhaled colistin without increasing the nephrotoxic-
ity risk [20–24]. In our study, aerosolised colistin was 
as effective as intravenous colistin in therapy of MDR 
bacilli VAP. Moreover, when analysing singly the items 
of the primary outcome, we find an improvement of oxy-
genation (i.e. P/F ratio) and a faster bacterial eradication 
time. A similar result was reported by Polat et al. [27] in 





















Fig. 5 a Incidence of acute renal failure (ARF) and necessity of replacement renal therapy (RRT) in both groups. b Mean time to ARF onset in both 
groups
Mean survival me (days):
AS colisn: 23.46 IV colisn:  23.56
Khi-deux ddl Sig.
Log Rank (Mantel-Cox) ,117 1 ,732
Fig. 6 Survival analysis in study groups
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bacteriological eradication within 3  days when inhaled 
colistin was combined with IV colistin. The meta-analysis 
of Valachis et  al. [28] reported a statistically significant 
improvement in clinical response and microbiologi-
cal eradication (OR 1.57; 95 % CI [1.14–2.15]; p = 0.006 
and OR 1.61; 95 % CI [1.11–2.35]; p = 0.01, respectively). 
These findings were not coherent with those of the meta-
analysis of Gua et al. [29] that did not show a difference 
in the microbiological response (OR 1.29, CI [0.63–2.63], 
p = 0.48).
The administration of colistin aerosol via a pneumatic 
Aeroneb® nebuliser requires some ventilator settings in 
order to maximise the intra-alveolar deposition. These 
conditions might participate in a better alveolar recruit-
ment and therefore may interfere with the improvement 
of P/F ratio in the intervention arm.
Systemic toxicity of inhaled colistin
Two types of toxicity, namely nephrotoxicity and neuro-
toxicity, have been reported with the uses of colistin. A 
systematic review of the toxicity of polymyxin revealed 
that in the old literature, incidences of both toxicities 
were reported to be considerably high, while new evi-
dence shows less toxicity than previously reported 
although the definition of nephrotoxicity was not stand-
ardised between the studies [30]. Renal toxicity of colistin 
has been described mainly with the intravenous route 
at high doses [31–33]. No increase of renal toxicity risk 
was reported in the studies that tested inhaled colistin 
as adjunctive therapy [20–24]. Likewise, in the study of 
Lu et al. [9] that compared AS colistin versus β-lactams, 
no difference was reported between renal toxicity’s inci-
dences (12 vs 8 %, p = 0.48). Else, it was shown that colis-
tin trough plasma concentration significantly increased 
between days 2 and 3, suggesting colistin accumulation 
with time as a result of slow systemic passage through the 
alveolar–capillary membrane [9].
Our findings asserted the hypothesis of low systemic 
diffusion of inhaled colistin. Indeed, we observed a signif-
icant higher incidence of ARF, a more frequent require-
ment of RRT and an earlier time to onset of ARF with 
parenteral administration.
The concurrent administration of nephrotoxic drugs, 
hypovolemia or shock, and severity of illness may 
increase the likelihood of the development of ARF. In 
the current study, the stratified analysis on exposure 
to nephrotoxic drugs showed that the association of IV 
colistin/IRA was independent of these factors (OR 2.81, 
CI 95 % [1.24–6.38], p = 0.012).
Overall incidence of neurotoxicity related to colis-
tin use is less than the nephrotoxicity. Earlier studies 
reported paresthesias in about one-fourth of patients 
Fig. 7 Duration of mechanical ventilation in study groups
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receiving colistin, with few case reports of neuromus-
cular blockade or apnea while recent studies did not 
report any significant neurotoxicity [10, 34–36]. Neuro-
toxicity is also dose-dependent and may be triggered by 
the presence of risk factors like the presence of hypoxia, 
co-administration of muscle relaxant, narcotics, seda-
tives or steroids. In our study, a neurotoxicity induced by 
colistin was probably observed in 9 (12 %) and 7 (9.2 %) 
among AS and IV groups, respectively. The only causal-
ity of colistin was uncertain given the co-administration 
of other neurotoxic drugs (narcotics, sedatives, steroids).
Local toxicity of inhaled colistin
Colistin aerosol inhalation therapy is generally well toler-
ated with few reported side effects like throat irritation, 
cough and bronchospasm, due to osmolality and preserv-
atives within some of the solutions [37]. Among our AS 
group, 2.7 % of patients presented a moderate bronchos-
pasm with a favourable evolution.
Impact on morbidity and mortality
Another benefit of inhaled colistin in addition to the 
renal safety was revealed in our series: the gain of 5 days 
on ventilator-free days in ICU survivors. That result was 
the main consequence of the rapidest bacterial eradica-
tion time and the better improvement of the P/F ratio in 
the AS group.
No differences were revealed in the other secondary 
outcomes: the length of stay and 28-day mortality. These 
results were coherent with those of several meta-analyses 
[28, 29, 38].
Lu et al. reported a prolonged ICU length of stay and 
a prolonged duration of ventilation in the aerosol group 
[9].
Acquisition of colistin resistance
It has been reported that prolonged use of IV colistin 
predisposes to VAP caused by pandrug-resistant bac-
teria, probably related to colistin poor lung tissue pen-
etration and low concentrations at the infection site [39, 
40], whereas nebulised colistin with a higher tissue con-
centrations in infected lung regions prevent selection of 
resistant strains [11]. On the other hand, acquisition of 
colistin resistance or increase in MICs was also reported 
and likely due to the incomplete destruction of the bron-
chial epithelium by colistin nebulisations and to produc-
tion of a biofilm that constitute a protective space for 
bacteria and facilitate selection of resistant mutants [41, 
42]. Low rates of acquisition of resistance were reported 
in recent studies [9, 29, 43]. As well, the current study did 
Fig. 8 Post-therapy assessment of Clinical Pulmonary Infection Score 
(CPIS) in study groups
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not detect an emergence of strains resistant to colistin 
acquisition. Yet, this finding must be interpreted reserv-
edly because of the short follow-up in our series.
Methodological limitations
The main limitation was the non-double-blind design 
of the trial protocol. Another pharmacologic limit was 
the absence of plasmatic dosages of colistin. These dos-
ages could preferentially assert our clinical and biological 
results of the low systemic diffusion of the inhaled route.
Conclusion
We conclude that the use of inhaled colistin seems to be 
beneficial in therapy of MDR bacilli VAP. Therapeutic 
effectiveness of such regimen was as effective as paren-
teral colistin. Further, it provided several benefits: a renal 
safety, a better improvement of P/F ratio, a shortened 
bacterial eradication time and an earlier weaning from 
ventilator in ICU survivors.
We suggest the regimen of aerosolised colistin as the 
first-line therapy in VAP due to MDR bacilli outside a 
septic shock and/or bacteraemia.
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